Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and mainly affects pre-menopausal and minority women. Because of the lack of ER, PR or HER2 expression in TNBC, there are limited options for tailored therapies. While TNBCs respond initially to standard of care chemother...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrew Takchi, Minzhi Zhang, Mohammad Jalalirad, Roberto Leon Ferre, Royal Shrestha, Tufia Haddad, Jann Sarkaria, Ann Tuma, Jodi Carter, Hillman David, Karthik Giridhar, Liewei Wang, Carol Lange, Urban Lendahl, James Ingle, Matthew Goetz, Antonino Bonaventura D’Assoro
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-05-01
coleção:	Frontiers in Oncology
Assuntos:	triple negative breast cancer immunotherapy cancer cell plasticity small molecule inhibitor organ metastases
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1384277/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!